文献速递临床试验与 GCP

维生素C对胰腺癌化疗相关贫血的疗效:一项随机对照试验的研究方案

Efficacy of vitamin C on chemotherapy-related anemia in pancreatic cancer: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2024-07-29

本研究为前瞻性、单中心、开放标签随机对照试验,计划于2023年9月至2026年9月在复旦大学附属肿瘤医院纳入至少100例伴远处转移的晚期胰腺腺癌患者,随机分为化疗组或化疗联合维生素C组。主要终点为贫血发生率,次要终点包括3级神经病变发生率、数字评定量表变化、生活质量和总生存期。旨在评估低剂量维生素C对接受吉西他滨联合白蛋白结合型紫杉醇化疗的转移性胰腺癌患者生活质量的影响。

要点

  • 化疗联合维生素C对比单纯化疗,主要终点为贫血发生率。
  • 纳入伴远处转移的晚期胰腺腺癌患者,计划样本量至少100例。
  • 次要终点包括3级神经病变发生率、数字评定量表变化、生活质量和总生存期。

核心结论

  • 本研究旨在评估低剂量维生素C对接受吉西他滨联合白蛋白结合型紫杉醇化疗的转移性胰腺癌患者生活质量的改善作用。

研究设计与样本

  • 前瞻性、单中心、开放标签随机对照试验,计划于2023年9月至2026年9月在复旦大学附属肿瘤医院开展。
  • 计划纳入至少100例伴远处转移的晚期胰腺腺癌患者,随机分配至化疗组或化疗联合维生素C组。

主要发现

  • 主要终点为贫血发生率,次要终点包括3级神经病变发生率、数字评定量表变化、生活质量和总生存期。

关键数值与推荐

  • 主要终点:贫血发生率。
  • 次要终点:3级神经病变发生率、数字评定量表变化、生活质量和总生存期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the treatment of advanced pancreatic cancer, chemotherapy plays a pivotal role. Despite its effectiveness, this regimen is often marred by side effects such as anemia, neuropathy, fatigue, nausea, and malnutrition, which significantly affect patients' tolerance to the treatment. Some studies have shown that vitamin C could potentially augment chemotherapy's tolerability, notably by boosting iron absorption, ameliorating anemia, and relieving pain and numbness in hands and feet. Nevertheless, the integration of vitamin C with chemotherapy to mitigate toxic side effects and enhance the quality of life for advanced pancreatic cancer patients has not been examined in any randomized controlled trials to date. METHODS: A prospective, single-center, open-label, randomized controlled trial will be conducted at Fudan University Shanghai Cancer Center from September 2023 to September 2026. A total of at least 100 patients with advanced pancreatic adenocarcinoma exhibiting distant metastases will be recruited and randomly assigned to the chemotherapy group or the chemotherapy plus vitamin C group. The primary endpoint is the rate of anemia. Secondary endpoints include the rate of grade 3 neuropathy, change of numeric rating scale, quality of life, and overall survival. DISCUSSION: This study aims to assess the impact of low-dose vitamin C on enhancing the quality of life for patients with metastatic pancreatic cancer undergoing gemcitabine and nab-paclitaxel chemotherapy. TRIAL REGISTRATION: The trial was registered with the ClinicalTrials.gov (NCT06018883) on August 31, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wang X, Zhu X, Liu Y, et al. Efficacy of vitamin C on chemotherapy-related anemia in pancreatic cancer: study protocol for a randomized controlled trial. Trials. 2024. PMID: 39075587. doi:10.1186/s13063-024-08345-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。